Abstract:As more patient data is cross-referenced with animal models of disease, the primary focus on Th1 autoreactive effector cell function in autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis, has shifted towards the role of Th17 autoreactive effector cells and the ability of regulatory T cells (Treg) to modulate the pro-inflammatory autoimmune response. Therefore, the currently favored hypothesis is that a delicate balance between Th1/17 effector cells and Treg cell function is critical in the regulation of inflammatory autoimmune disease. An intensive area of research with regard to the Th1/17:Treg cell balance is the utilization of blockade and/or ligation of various co-stimulatory or co-inhibitory molecules, respectively, during ongoing disease to skew the immune response toward a more tolerogenic/regulatory state. Currently, FDA-approved therapies for multiple sclerosis patients are all aimed at the suppression of immune cell function. The other favored method of treatment is a modulation or deletion of autoreactive immune cells via short-term blockade of activating co-stimulatory receptors via treatment with fusion proteins such as CTLA4-Ig and CTLA4-FasL. Based on the initial success of CTLA4-Ig, there are additional fusion proteins that are currently under development. Examples of the more recently identified B7/CD28 family members are PD-L1, PD-L2, inducible co-stimulatory molecule-ligand (ICOS-L), B7-H3, and B7-H4, all of which may emerge as potential fusion protein therapeutics, each with unique, yet often overlapping functions. The expression of both stimulatory and inhibitory B7 molecules seems to play an essential role in modulating immune cell function through a variety of mechanisms, which is supported by findings that suggest each B7 molecule has developed its own indispensable niche in the immune system. As more data are generated, the diagnostic and therapeutic potential of the above B7 family-member-derived fusion proteins becomes ever more apparent. Besides defining the biology of these B7/CD28 family members in vivo, additional difficulty in the development of these therapies lies in maintaining the normal immune functions of recognition and reaction to non-self-antigens following viral or bacterial infection in the patient. Further complicating the clinical translation of these therapies, the mechanism of action identified for a particular reagent may depend upon the method of immune-cell activation and the subset of immune cells targeted in the study.

CTLA-4: From mechanism to autoimmune therapy

Current understanding of CTLA-4: from mechanism to autoimmune diseases

Beyond T-Cells: Functional Characterization of CTLA-4 Expression in Immune and Non-Immune Cell Types

CTLA-4 in Regulatory T Cells for Cancer Immunotherapy

Molecular and Cellular Functions of CTLA-4.

An overview on the interaction between non-coding RNAs and CTLA-4 gene in human diseases

Altered Ligand-Interaction Contributes to Functional Insufficiency Due to CTLA-4 Gene Mutation

Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy

Challenges and opportunities in targeting the CD28/CTLA-4 pathway in transplantation and autoimmunity

Taming tissue-specific T cells: CTLA-4 reins in self-reactive T cells

Cutting Edge: CTLA-4–B7 Interaction Suppresses Th17 Cell Differentiation

Understanding the cellular and molecular mechanism of anti-CTLA4 mediated tumor rejection

B7 Interactions with CD28 and CTLA-4 Control Tolerance or Induction of Mucosal Inflammation in Chronic Experimental Colitis

CTLA4 Message Reflects Pathway Disruption in Monogenic Disorders and Under Therapeutic Blockade

Cellular and molecular signaling towards T cell immunological self-tolerance

Addressing the Elephant in the Immunotherapy Room: Effector T-Cell Priming versus Depletion of Regulatory T-Cells by Anti-CTLA-4 Therapy

Elucidating CTLA-4's role in tumor immunity: a comprehensive overview of targeted antibody therapies and clinical developments

Targeting the B7 Family of Co-Stimulatory Molecules

CTLA-4 expression by B-1a B cells is essential for immune tolerance

Exploring The Main Mechanisms Of Anti-Tumor And Immunotherapy-Related Adverse Events For Safer And Effective Anti-Ctla-4 Immunotherapy

TLR2 and TLR4 in autoimmune diseases: a comprehensive review